Development of a Coagulation Disorders Unit

Abstract

Our Coagulation Disorders Unit in Helsinki, Finland, provides 24/7 services for local and national hospitals and colleagues upon requests regarding bleeding and thrombosis diagnostics and management, including follow-up. The unit has a tight connection between the clinic and laboratory, and its maintenance and sharing knowledge and observations have been priorities, already for over 20 years and will continue to be of major importance. The consultation service is provided by phone during daytime and on-call hours, and in written form sent electronically to the consulting stakeholders. Thrombosis and hemostasis-targeted outpatient clinics are also available for the patients referred to the center. Writing local guidance and official guidelines, Nordic, European and international collaboration, and educational activities including social communication are critical elements for the Coagulation Disorders Unit. Alertness to acute coagulation abnormalities, such as occurred during COVID-19 and vaccine-induced thrombosis and thrombocytopenia, and development of strategies to manage cross-disciplinary problems are topics which call upon broad networking. The Nordic community has an ongoing historical meeting, which has been circulating among coagulation centers for the past 56 years. At the European level, the European Association of Haemophilia and Allied Disorders focuses on bleeding disorders and their management, including safety surveillance. The International Society of Thrombosis and Haemostasis offers excellent basic and clinical benchmarks for any Coagulation Disorders Unit. We hope that the description of the development and implementation of our Coagulation Disorders Unit in Helsinki achieves international interest and broadens international collaboration. Finally, we congratulate STH on its great contributions around the globe and for providing a vivid forum to foster the discipline of thrombosis and hemostasis.

Keywords

coagulation disorders - hemophilia - von Willebrand disease - thrombosis - anticoagulation clinic

Publication History

Article published online:
19 February 2024

• References

• 1 Makris M, Calizzani G, Fischer K. et al. The European Haemophilia Network (EUHANET). Blood Transfus 2014; 12 (Suppl 3, Suppl 3): s515-s518
• 2 Lassila R. Role and management of coagulation disorders in peripheral arterial disease. Scand J Surg 2012; 101 (02) 94-99
• 3 Szanto T, Lassila R, Funding E. on behalf of the Nordic Haemophilia Council. Von Willebrand disease – the Nordic perspective. Ann Blood 2018; 3: 1-10
• 4 Szanto T, Zetterberg E, Ramström S. et al; Nordic Haemophilia Council. Platelet function testing: current practice among clinical centres in Northern Europe. Haemophilia 2022; 28 (04) 642-648
• 5 Pikta M, Zemtsovskaja G, Bautista H. et al. Preclinical evaluation of a semi-automated and rapid commercial electrophoresis assay for von Willebrand factor multimers. J Clin Lab Anal 2018; 32 (06) e22416
• 6 Helin T, Joutsi-Korhonen L, Lassila R. Clinical use and laboratory testing of oral anticoagulation therapy: experience from Finland. Ann Blood 2019; 4: 17-22
• 7 Szanto T, Nummi V, Jouppila A, Brinkman HJM, Lassila R. Platelets compensate for poor thrombin generation in type 3 von Willebrand disease. Platelets 2020; 31 (01) 103-111
• 8 Szántó T, Joutsi-Korhonen L, Deckmyn H, Lassila R. New insights into von Willebrand disease and platelet function. Semin Thromb Hemost 2012; 38 (01) 55-63
• 9 Jenkins PV, Bowyer A, Burgess C. et al. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia 2020; 26 (01) 151-155
• 10 Szanto T, Vaide I, Jouppila A, Lemponen M, Lassila R. Thromboelastometry detects enhancement of coagulation in blood by emicizumab via intrinsic pathway. Haemophilia 2021; 27 (04) e571-e574
• 11 Ljungkvist M, Strandberg K, Berntorp E. et al. Evaluation of a standardized protocol for thrombin generation using the calibrated automated thrombogram: a Nordic study. Haemophilia 2019; 25 (02) 334-342
• 12 Nummi V, Lehtinen AE, Iorio A, Szanto T, Lassila R. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: comparison of factor product use, bleed rates and pharmacokinetics. Haemophilia 2022; 28 (06) e237-e244
• 13 Yu JK, Iorio A, Edginton AN. WAPPS co-investigators. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: a scoping review. Res Pract Thromb Haemost 2019; 3 (03) 528-541
• 14 Pitkänen HH, Jouppila A, Helin T. et al. COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets. Thromb Res 2021; 208: 129-137
• 15 Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost 2012; 38 (01) 23-30
• 16 Helin TA, Pakkanen A, Lassila R, Joutsi-Korhonen L. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem 2013; 59 (05) 807-814
• 17 Hindricks G, Potpara T, Dagres N. et al; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (05) 373-498
• 18 Gray E, Kitchen S, Bowyer A. et al. Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: a United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia 2020; 26 (01) 6-16